)
Adverse events occurring in ≥5% of patients aged 1-11 years treated with DUPIXENT
and greater than placebo through 16 weeks1
The safety profile of DUPIXENT through Week 16 of the EoE KIDS clinical study was generally similar to the safety profile in adult and pediatric patients 12 years of age and older with EoE. In Part B, a helminth infection was reported in one DUPIXENT-treated subject.2
ATTRIBUTES AND CONSIDERATIONS FOR DUPIXENT2
NO BOXED WARNING
Please see additional Warnings and
Precautions in the Prescribing Information
and Important Safety Information below.
no known drug-to-drug
interactions
Not metabolized through the liver or excreted
through the kidneys.
DUPIXENT IS NOT AN
IMMUNOSUPPRESSANT
NO REQUIREMENT FOR INITIAL LAB
TESTING OR ONGOING LAB MONITORING,
according to the Prescribing information
IMPORTANT SAFETY INFORMATION
SELECT WARNING AND PRECAUTION
Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. A case of AGEP was reported in an adult subject who participated in the bullous pemphigoid development program. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.
Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.
DOSAGE AND ADMINISTRATION
Thinking about prescribing DUPIXENT? Find the information you need to get started.